This observation suggests that restoring relatively low levels of LCAT activity, perhaps comparable to those seen in FED patients, may be sufficient to prevent renal disease and poses the basis for the determination of a “therapeutic” threshold of activity that may be used as clinical endpoint. This evidence concerns the gene LCAT and fish eye disease.